Replies to post #110775 on Regen BioPharma Inc (RGBP)

[29YEARINVESTOR]

Volume precedes Price! Them Fudpucker naked short and distort MM’s and there crony Twitter bashers will always bash RGBP and it’s shareholders. Yet now that debt is gone. They know more good news is on the way and even with all there naked shorting and distorting they can’t stop the Big Fun RGBP runs or even the Mini runs. That should be sustained once the right News, deal, partner or buyout comes along!
A good strategy is while holding a core position. Buy extra shares on the dips and sell them on the ripping runs. Always holding a core for the next 1,000% to 10,000% runs like RGBP had twice last year!
Wash, Rinse and Repeat for much profits and Free Riding Core position.
RGBP is a Traders Dream and a no brainer at this point!

In 2021 the Company was granted US patent # 11,090,332 on composition of matter of survivin modified-mRNA useful for teaching the immune system to kill cancer. In the current patent, specific types of dendritic cells, means of generating specialized dendritic cells, and the planned formulation that will enter clinical trials have been granted patent protection.
https://www.prnewswire.com/news-releases/regen-biopharma-inc--files-provisional-patent--application-on-second-generation-survivin-mrna-cancer-immunotherapy-vaccine-301593795.html
Dr. David KOO’s is a Business Leader and has always put together a great team the Ichims being the cream of the crop!
KOO’s owns 38+% or 169+ million shares of RGBP preferred shares RGBPP!

Dr. David KOO’s has 169 Million reasons for making RGBP Great Again!
KOO’s owns 169+ million shares of RGBPP preferred shares or 169 million reasons to see that RGBP is successful.
https://www.marketscreener.com/business-leaders/David-Raymond-Koos-06H0YV-E/biography/

Check it out RGBP on the Fast Track!
https://www.yahoo.com/now/regen-biopharma-inc-announces-program-120000581.html
Things looking up here:
San Diego, CA, March 30, 2022: Regen BioPharma, Inc. received communication from the U.S. Patent Office that certain claims in its application #15/820,324 entitled, “Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans” have been allowed. $RGBP $RGBPP 1:39 PM · Mar 30, 2022·[/b
]

San Diego, CA, March 30, 2022: Regen BioPharma, Inc. received communication from the U.S. Patent Office that certain claims in its application #15/820,324 entitled, “Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans” have been allowed.$RGBP $RGBPP

— Regen BioPharma Inc. (@TheRegenBio) March 30, 2022

On the next Big Fun RGBP Run with the right News, Deal, Partner or Buyout RGBP should get get the mother of all the RGBP Naked Short Squeezes IMO!

Now RGBP has much more going for us!
Regen BioPharma Inc's Company Profile
Business Description
Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.